MedTrace Logo

D-Cycloserine for Serine Palmitoyltransferase Inhibition

NCT07542548 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-04-21

No results posted yet for this study

Summary

The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia

Conditions

  • Hereditary Spastic Paraplegia

Interventions

DRUG

D-cycloserine

Pyridoxine also prescribed to help prevent neurologic adverse events related to D-Cycloserine.

Sponsors & Collaborators

  • Uniformed Services University of the Health Sciences

    collaborator FED

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
6 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2026-03-17
Completion
2026-03-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07542548 on ClinicalTrials.gov